CING Cingulate Inc

USD 0.88 0.04 4.77381
Icon

Cingulate Inc (CING) Stock Analysis and Price Targets

COMMON STOCK | Biotechnology | NSD
stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

Strong Buy

Top Analyst
Rating
stockTargetAdvisor

Very Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

Strong Buy

Average User
Rating

USD 0.8801

+0.04 (+4.77)%

USD 5.32M

8.65K

USD 8.00(+808.99%)

USD 3.43 (+289.73%)

Icon

CING

Cingulate Inc (USD)
COMMON STOCK | NSD
USD 0.88
0.00 0
Take a Tour
stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

Strong Buy

Top Analyst
Rating
stockTargetAdvisor

Very Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

Strong Buy

Average User
Rating

USD 5.32M

USD 3.43 (+289.73%)

USD 0.88

Cingulate Inc (CING) Stock Forecast

Show ratings and price targets of :
USD 8.00
(+808.99%)

Based on the Cingulate Inc stock forecast from 1 analysts, the average analyst target price for Cingulate Inc is USD 8.00 over the next 12 months. Cingulate Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Cingulate Inc is Very Bearish, which is based on 0 positive signals and 6 negative signals. At the last closing, Cingulate Inc’s stock price was USD 0.8801. Cingulate Inc’s stock price has changed by +0.11% over the past week, -20.71% over the past month and -95.89% over the last year.

No recent analyst target price found for Cingulate Inc
No recent average analyst rating found for Cingulate Inc

Company Overview Cingulate Inc

Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial,...Read More

https://www.cingulate.com

1901 West 47th Place, Kansas City, KS, United States, 66205

13

December

USD

USA

Adjusted Closing Price for Cingulate Inc (CING)

Loading...

Unadjusted Closing Price for Cingulate Inc (CING)

Loading...

Share Trading Volume for Cingulate Inc Shares

Loading...

Compare Performance of Cingulate Inc Shares

Symbol Capital Gain Dividend Return Total Return
Loading...
Loading...

Technical Indicators for CING

Assets

Top Holdings

Top Sectors

Top Regions

Stocks Similar To Cingulate Inc (Sector: Biotechnology )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX
Vertex Pharmaceuticals Inc -0.22 (-0.06%) USD107.38B 29.93 21.06

ETFs Containing CING

Symbol Name CING's Weight Expense Ratio Price(Change) Market Cap
no data

Frequently Asked Questions About Cingulate Inc (CING) Stock

Based on ratings from 1 analysts Cingulate Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Very Bearish. The stock has 1 buy, sell and hold ratings.

Unfortunately we do not have enough data on CING's stock to indicate if its a good dividend stock.

Based on targets from 1 analysts, the average taret price for CING is USD 8.00 over the next 12 months. The maximum analyst target price is USD 8 while the minimum anlayst target price is USD 8.

Unfortunately we do not have enough data on CING's stock to indicate if its overvalued.

The last closing price of CING's stock was USD 0.88.

The most recent market capitalization for CING is USD 5.32M.

Based on targets from 1 analysts, the average taret price for CING is projected at USD 8.00 over the next 12 months. This means that CING's stock price may go up by +808.99% over the next 12 months.

We can't find any ETFs which contains Cingulate Inc's stock.

As per our most recent records Cingulate Inc has 13 Employees.

Cingulate Inc's registered address is 1901 West 47th Place, Kansas City, KS, United States, 66205. You can get more information about it from Cingulate Inc's website at https://www.cingulate.com.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...